137 related articles for article (PubMed ID: 10616550)
1. Improving management of type 2 diabetes mellitus: 3. Sulfonylureas.
Samraj GP; Quillen DM; Kuritzky L
Hosp Pract (1995); 1999 Nov; 34(12):129-34, 137, 140. PubMed ID: 10616550
[No Abstract] [Full Text] [Related]
2. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
Furukawa H; Ishida H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
[No Abstract] [Full Text] [Related]
3. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
4. The UK Prospective Diabetes Study.
Evans M
Lancet; 1998 Dec; 352(9144):1932-3; author reply 1934. PubMed ID: 9863807
[No Abstract] [Full Text] [Related]
5. The UK Prospective Diabetes Study.
Bailey CJ; Grant PJ
Lancet; 1998 Dec; 352(9144):1932; author reply 1934. PubMed ID: 9863806
[No Abstract] [Full Text] [Related]
6. The UK Prospective Diabetes Study.
Kerner W
Lancet; 1998 Dec; 352(9144):1934. PubMed ID: 9863811
[No Abstract] [Full Text] [Related]
7. Warfarin with sulfonylureas and hypoglycemic events: consider dose, length of treatment, and all sulfonylureas.
Bosco-Lévy P; Salvo F
BMJ; 2016 Aug; 354():i4328. PubMed ID: 27495245
[No Abstract] [Full Text] [Related]
8. [Combined insulin-sulfonylurea in type II diabetes mellitus--an update].
Ravina A; Minuchin O
Harefuah; 1987 Nov; 113(10):285-7. PubMed ID: 3326798
[No Abstract] [Full Text] [Related]
9. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
10. Progressing From Metformin to Sulfonylureas or Meglitinides.
Grant JS; Graven LJ
Workplace Health Saf; 2016 Sep; 64(9):433-9. PubMed ID: 27621259
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for NIDDM: has its time arrived?
Menke J
S D J Med; 1995 Aug; 48(8):246-7. PubMed ID: 7569874
[No Abstract] [Full Text] [Related]
12. Sulfonylureas.
Zimmerman BR
Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
[TBL] [Abstract][Full Text] [Related]
13. [Minor differences in outcome comparing early vs. later initiation of medicamentous blood glucose control in type 2 diabetic patients].
Ritzman P
Praxis (Bern 1994); 1999 Aug; 88(31-32):1289-90. PubMed ID: 10479970
[No Abstract] [Full Text] [Related]
14. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
15. Emergency management of oral hypoglycemic drug toxicity.
Rowden AK; Fasano CJ
Emerg Med Clin North Am; 2007 May; 25(2):347-56; abstract viii. PubMed ID: 17482024
[TBL] [Abstract][Full Text] [Related]
16. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
[TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of diabetes mellitus].
Kaneko T
Nihon Naika Gakkai Zasshi; 1993 Mar; 82(3):406-9. PubMed ID: 8315336
[No Abstract] [Full Text] [Related]
18. Pareto's law and sulfonylureas.
Peiris AN; Micklewright M; Gangadharan V
South Med J; 2007 Nov; 100(11):1072-3. PubMed ID: 17984734
[No Abstract] [Full Text] [Related]
19. [Combination therapy with insulin and sulfonylurea].
Takamatsu J
Nihon Rinsho; 1997 Nov; 55 Suppl():255-60. PubMed ID: 9434477
[No Abstract] [Full Text] [Related]
20. Authors' reply to Tufan and colleagues and Boucaud-Maitre.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 Jun; 353():i3188. PubMed ID: 27267359
[No Abstract] [Full Text] [Related]
[Next] [New Search]
